Skip to main content
main-content

08.04.2016 | Original Communication | Ausgabe 6/2016

Journal of Neurology 6/2016

Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study

Zeitschrift:
Journal of Neurology > Ausgabe 6/2016
Autoren:
Sophie Drapier, Alexandre Eusebio, Bertrand Degos, Marc Vérin, Franck Durif, Jean Philippe Azulay, François Viallet, Tiphaine Rouaud, Caroline Moreau, Luc Defebvre, Valerie Fraix, Christine Tranchant, Karine Andre, Christine Brefel Courbon, Emmanuel Roze, David Devos
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00415-016-8106-3) contains supplementary material, which is available to authorized users.
OPTIPUMP Study Group. Members of the OPTIPUMP Study Group are present in Acknowledgements.

Abstract

To report on OPTIPUMP, a cohort study, investigating the impact in real-life clinical settings of continuous subcutaneous apomorphine infusion (CSAI) on the quality of life (HRQoL) of patients with Parkinson’s disease. OPTIPUMP was a prospective, open-label, observational cohort study involving 30 investigational sites in France. CSAI was proposed as part of routine clinical care to patients aged ≥18 years, in absence of dementia, with a PD diagnosis and based on the presence of motor fluctuations not controlled by oral treatments. The impact of APO-pump on quality of life was evaluated as the difference in PDQ-39 scores between the initiation treatment and the follow-up visit after 6 months’ treatment. All adverse events were recorded. Hyper- and hypodopaminergic behavioral tolerance was assessed on the Ardouin Scale of Behavior in Parkinson’s Disease. Between September 2011 and January 2013, we enrolled 142 patients: 42 patients were withdrawn due to pump removal (33), death (4), lost of follow-up (4), no available data (1). 100 completed the study. At 6 months, their HRQoL had significantly improved (p = 0.011), as had their total UPDRS score (p < 0.001). Regarding the safety profile, Ardouin scale scores indicated that their hyperdopaminergic behaviors had not increased. CSAI had a favorable impact on HRQoL, with benefits outweighing risks. The analysis of the withdrawn patients highlights the heterogeneity of the use of the pump having an impact on its efficacy and tolerability.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt e.Med zum Sonderpreis bestellen!

Sichern Sie sich jetzt Ihr e.Med-Abo und sparen Sie 50 %!

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary Fig. 1. Treatment changes during the study (DOCX 34 kb)
Supplementary Fig. 2. UPDRS scores at baseline and 6 months after CSAI initiation (DOCX 26 kb)
Supplementary Table 1. Apomorphine doses and rates between CSAI initiation and 6-month follow up (DOCX 17 kb)
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 6/2016

Journal of Neurology 6/2016 Zur Ausgabe
  1. Sie können e.Med Neurologie & Psychiatrie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Sie können e.Med Neurologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.